Drug intelligence / Profile preview

ARTS-021

Development stage: Phase 2
Lead developer: Avenzo Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

ARTS-021 is an orally bioavailable, highly potent and selective small molecule inhibitor of cyclin-dependent kinase 2 (CDK2), a key enzyme involved in cell cycle regulation. By inhibiting the CDK2/CyclinE1 complex, it disrupts abnormal cell proliferation driven by CCNE1 amplification or cyclin E overexpression. The drug is being developed primarily for the treatment of advanced solid tumors, including hormone receptor positive/HER2 negative breast cancer and CCNE1-amplified cancers. It may also be used in combination with CDK4/6 inhibitors to overcome resistance mechanisms in certain cancers. The developer is Avenzo Therapeutics, with Allorion Therapeutics as the originator.

Other names: AVZO-021AVZO021AVZO 021ARTS-021ARTS021ARTS 021

Targets

CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on ARTS-021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ARTS-021.

Explore the full profile